Directors and Senior Management
Executive Directors
Non-executive Directors
Senior Management
Executive Directors
Andrew Heath, MD, PhD
(Chief Executive Officer) (60)
Andrew Heath holds a MD and PhD from Sweden’s Gothenburg University. After a career in research and clinical medicine at Vanderbilt University, the joined the pharmaceutical industry in 1989. Dr Heath has held both R&D and commercial positions with Glaxo and Astra, in Europe and the US. He served as Chief Executive Officer at AeroGen Inc. from 1996, joining Therapeutic Antibodies Inc as Chief Executive Officer in March 1998. He continued as Chief Executive Officer upon the formation of Protherics in 1999 following the merger of Therapeutic Antibodies Inc and Proteus International plc. Dr Heath is a Non-executive Director of XL TechGroup Inc and the BioIndustry Association.
Rolf Soderstrom, BA, ACA
(Finance Director) (42)
Rolf Soderstrom joined the Board of Protherics in August 2007. After qualifying as a Chartered Accountant, he worked in the Corporate Recovery and Corporate Finance department of PricewaterhouseCoopers. In 2000 he joined Cable & Wireless plc as a Director of Corporate Finance where he managed M&A and funding opportunities, and was responsible for a range of listed investments. In 2004 he joined Cobham plc as a Divisional Finance Director managing a portfolio of businesses across Europe and the USA. He is a trustee of the Protherics pension scheme.
James Christie, BSc, MBA
(Operations Director) (50)
James Christie joined the biopharmaceutical industry in 1980 and has worked with GSK, Celltech and Centocor BV, before joining Therapeutic Antibodies Inc. in 1998. He was appointed to the Protherics Board in September 1999. He has management responsibility for manufacturing, quality, process development and technical support operations in Australia, the UK and Salt Lake City. He is also a trustee of the Protherics pension scheme. Mr Christie played a major part in the negotiations with AstraZeneca, leading to the licensing agreement in December 2005 and more recently in establishing the manufacturing operation for OncoGel™ after the MacroMed acquisition in January 2007.
Saul Komisar, BS, MBA
(President Protherics Inc.) (39)
Saul Komisar joined Therapeutic Antibodies Inc. in December 1996 prior to its merger with Proteus International plc to form Protherics PLC, having spent the previous six years working in corporate finance and banking, specialising in the healthcare industry. He has served as President of Protherics Inc. since November 2000 and was appointed to the Board of Protherics PLC in April 2007. Mr Komisar has responsibility for Protherics’ US operations. He holds a MBA from the Owen Graduate School of Management at Vanderbilt University and is a Non-executive Director of Franklin Synergy Bank, a US commercial retail bank. Mr. Komisar has also served on the Boards of several non-profit and volunteer organisations.
Top of page
Non-executive Directors
Stuart Wallis, FCA, CTA
(Non-executive Chairman) (62)
Stuart Wallis became Chairman of Therapeutic Antibodies Inc in September 1998 and in 1999, following the merger of Therapeutic Antibodies Inc. and Proteus International plc, he became Chairman of Protherics. He was previously the Chief Executive Officer of Fisons plc and Chairman of Communisis plc and is currently Chairman of Plethora Solutions Holdings PLC, The Simply Smart Group Ltd, TSL Education Ltd, BCS Global Networks Ltd, LGC Group Holdings Plc and a director of other private companies.
John Brown, PhD, MBA, FRSE (53)
John Brown joined the Board of Protherics in March 2004 and was previously the Chief Executive Officer of Acambis PLC having previously held the position of Finance Director. He is currently the Chairman of the Roslin Institute and Scottish Biomedical Ltd and CXR Biosciences. He is a Non-executive Director of several companies including Vectura Group plc and Ardana plc. He is a member of the Technology Strategy Board and is Chairman of the Roslin Foundation.
Jacques Gonella, PhD (66)
Jacques Gonella joined the Board of Protherics in January 2007 following the acquisition of MacroMed Inc. (now Protherics Salt Lake City Inc.) Prior to the acquisition, he was a Non-executive Director of MacroMed, joining its Board in 1999 in connection with an equity investment in the company. He is the principal in the consulting firm of JG Consulting AG and is the founder of Permatec, which merged with Mediject in 2001 to form Antares Pharma, Inc., a US public device company. Dr Gonella also serves as Chairman of the Board of Directors of Antares Pharma. Prior to founding Permatec, he founded JAGO Pharma AG in 1983 and served as its President and Chief Executive Officer until its acquisition in May 1996 by SkyePharma PLC. Before founding JAGO, he occupied various positions with F. Hoffmann La Roche Ltd. and Pfizer Inc. between 1968 and 1979. He holds a doctorate in analytical chemistry from the Polytechnic Institute of Lausanne, Switzerland.
Bryan Morton, BSc, MBA (52)
Bryan Morton joined the Board of Protherics in July 2005. He has a BSc in Pharmacology from Aberdeen University and a MBA from Durham University. Mr Morton began his pharmaceutical career in sales and has held positions in medical information, marketing, sales management, business development and general management during a 30 year career in the healthcare industry, largely with Merck and Co. Inc. and Bristol Myers Squibb. In 2003 founded Zeneus Pharma, which was sold to Cephalon Inc in late 2005, Mr Morton subsequently founded and is CEO of a new speciality pharmaceutical company EUSA Pharma, Inc., a speciality pharmaceutical company.. He is a Non-executive Director of Aircraft Medical Ltd, a medical device company and is a member of the Pilgrim Software global advisory board.
Garry Watts, FCA (51)
Garry Watts joined the Board of Protherics in February 2004. He is currently the Chief Executive Officer of SSL International PLC having previously held the position of Finance Director and Managing Director for Europe. He is also a Non-executive Director of Stagecoach PLC, where he chairs the Audit and Risk Committee and of the MHRA. Previously, Mr Watts held executive directorships at Celltech Group plc and Medeva plc. He is a chartered accountant and was previously a partner with KPMG, leading the UK healthcare and life science practice.
Top of page
Business Development
Ian Scoular, PhD
(Director of Business Development) (58)
Ian Scoular has more than 20 years business development expertise in the pharmaceutical industry through positions in Nycomed, Schering Plough and Reckitt & Colman. Dr Scoular joined Protherics PLC in July 2002 where he is responsible for seeking commercial partners for Protherics' development products and intellectual property portfolio.
Corporate Development and Investor Relations
Nick Staples, PhD
(Director of Corporate Affairs) (38)
Nick Staples joined Protherics in November 2003 and is responsible for corporate development and investor relations. He was previously a biotechnology analyst at WestLB Panmure and spent four years as a management consultant in the Life Sciences Practice at PA Consulting Group, gaining experience in strategic planning, business analysis and due diligence. He holds a PhD in Biochemistry from the University of Cambridge.
Research & Development
Sally Waterman, PhD
(Director of Research & Development) (50)
Sally Waterman has over 25 years experience within the pharmaceutical industry. She previously served as Director of Development Operations at Xenova Group plc, following its acquisition of KS Biomedix Holdings plc, where she was Vice President of Research and Development. Prior to this, Dr Waterman held various senior positions within Vanguard Medica plc (now Vernalis plc), including Vice President of Non-Clinical Development.
Sales and Marketing
David Briscoe
(Director of Marketing and Sales - Europe)
David Briscoe joined Protherics in November 2004 to build Protherics' commercial activities within the EU. He joins the company after spending over 25 years in sales and operational roles, mainly in oncology, with companies such as Chiron, Bristol Myers, Schering Plough and Incyte.
Top of page